文献速递泌尿男性生殖肿瘤

卡巴他赛对比多西他赛一线治疗转移性去势抵抗性前列腺癌:随机III期FIRSTANA试验

Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA.
PubMed 文献 · J Clin Oncol · 2017-07-28

FIRSTANA研究将1168例未接受化疗的转移性去势抵抗性前列腺癌患者随机分至卡巴他赛20 mg/m2、25 mg/m2或多西他赛75 mg/m2组,每3周静脉给药联合每日泼尼松。主要终点总生存期在三组间无显著差异,卡巴他赛25 mg/m2组影像学肿瘤缓解率数值上高于多西他赛组,但毒性谱不同。

要点

  • 卡巴他赛20或25 mg/m2的总生存期未优于多西他赛75 mg/m2。
  • 卡巴他赛25 mg/m2组3/4级治疗中出现的不良事件发生率为60.1%,高于多西他赛组的46.0%。
  • 卡巴他赛20 mg/m2组总体毒性低于卡巴他赛25 mg/m2组和多西他赛组。

核心结论

  • 在未接受化疗的转移性去势抵抗性前列腺癌患者中,卡巴他赛20 mg/m2和25 mg/m2的总生存期未优于多西他赛75 mg/m2。

研究设计与样本

  • 随机III期FIRSTANA试验(ClinicalTrials.gov识别号:NCT01308567),纳入体能状态评分0至2分的转移性去势抵抗性前列腺癌患者。
  • 2011年5月至2013年4月期间,1168例患者按1:1:1随机分配至卡巴他赛20 mg/m2组、卡巴他赛25 mg/m2组或多西他赛75 mg/m2组,每3周静脉给药联合每日泼尼松。
  • 主要终点为总生存期,次要终点包括安全性、无进展生存期、肿瘤/前列腺特异性抗原/疼痛缓解、药代动力学和健康相关生活质量。

主要发现

  • 中位总生存期:卡巴他赛20 mg/m2组24.5个月,卡巴他赛25 mg/m2组25.2个月,多西他赛75 mg/m2组24.3个月。
  • 卡巴他赛20 mg/m2对比多西他赛75 mg/m2的风险比(HR)为1.01(95%CI 0.85至1.20;P=.997);卡巴他赛25 mg/m2对比多西他赛75 mg/m2的HR为0.97(95%CI 0.82至1.16;P=.757)。
  • 中位无进展生存期:卡巴他赛20 mg/m2组4.4个月,卡巴他赛25 mg/m2组5.1个月,多西他赛75 mg/m2组5.3个月,组间无显著差异。
  • 影像学肿瘤缓解率:卡巴他赛25 mg/m2组41.6%对比多西他赛75 mg/m2组30.9%,名义P=.037,未进行多重检验校正。
  • 3或4级治疗中出现的不良事件发生率:卡巴他赛20 mg/m2组41.2%,卡巴他赛25 mg/m2组60.1%,多西他赛75 mg/m2组46.0%。

关键数值与推荐

  • 卡巴他赛25 mg/m2组发热性中性粒细胞减少、腹泻和血尿发生率高于多西他赛75 mg/m2组。
  • 多西他赛75 mg/m2组周围神经病变、外周水肿、脱发和指甲疾病发生率高于卡巴他赛25 mg/m2组。
  • 卡巴他赛25 mg/m2对比多西他赛75 mg/m2的疼痛无进展生存期数值上多西他赛组更优。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose In patients with metastatic castration-resistant prostate cancer (mCRPC), overall survival (OS) is significantly improved with cabazitaxel versus mitoxantrone after prior docetaxel treatment. FIRSTANA ( ClinicalTrials.gov identifier: NCT01308567) assessed whether cabazitaxel 20 mg/m2 (C20) or 25 mg/m2 (C25) is superior to docetaxel 75 mg/m2 (D75) in terms of OS in patients with chemotherapy-naïve mCRPC. Patients and Methods Patients with mCRPC and Eastern Cooperative Oncology Group performance status of 0 to 2 were randomly assigned 1:1:1 to receive C20, C25, or D75 intravenously every 3 weeks plus daily prednisone. The primary end point was OS. Secondary end points included safety; progression-free survival (PFS); tumor, prostate-specific antigen, and pain response; pharmacokinetics; and health-related quality of life. Results Between May 2011 and April 2013, 1,168 patients were randomly assigned. Baseline characteristics were similar across cohorts. Median OS was 24.5 months with C20, 25.2 months with C25, and 24.3 months with D75. Hazard ratio for C20 versus D75 was 1.01 (95% CI, 0.85 to 1.20; P = .997), and hazard ratio for C25 versus D75 was 0.97 (95% CI, 0.82 to 1.16; P = .757). Median PFS was 4.4 months with C20, 5.1 months with C25, and 5.3 months with D75, with no significant differences between treatment arms. Radiographic tumor responses were numerically higher for C25 (41.6%) versus D75 (30.9%; nominal P = .037, without multiplicity test adjustment). Rates of grade 3 or 4 treatment-emergent adverse events were 41.2%, 60.1%, and 46.0% for C20, C25, and D75, respectively. Febrile neutropenia, diarrhea, and hematuria were more frequent with C25; peripheral neuropathy, peripheral edema, alopecia, and nail disorders were more frequent with D75. Conclusion C20 and C25 did not demonstrate superiority for OS versus D75 in patients with chemotherapy-naïve mCRPC. Tumor response was numerically higher with C25 versus D75; pain PFS was numerically improved with D75 versus C25. Cabazitaxel and docetaxel demonstrated different toxicity profiles, with overall less toxicity with C20.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Oudard S, Fizazi K, Sengeløv L, et al. Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA. J Clin Oncol. 2017. PMID: 28753384. doi:10.1200/JCO.2016.72.1068

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。